StockNews.com Downgrades Lipocine (NASDAQ:LPCN) to Hold

Lipocine (NASDAQ:LPCN) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.

Lipocine Stock Up 2.2 %

NASDAQ LPCN opened at $3.67 on Friday. The stock has a market capitalization of $19.63 million, a P/E ratio of -2.15 and a beta of 1.12. Lipocine has a 52-week low of $2.31 and a 52-week high of $11.79. The firm has a 50-day moving average price of $5.67 and a 200 day moving average price of $5.50.

Lipocine (NASDAQ:LPCN) last issued its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter. The business had revenue of $0.09 million for the quarter. On average, equities research analysts expect that Lipocine will post -1 earnings per share for the current fiscal year.

Institutional Trading of Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP acquired a new stake in shares of Lipocine Inc. (NASDAQ:LPCN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine at the end of the most recent reporting period. Institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.